Migraine diagnosis and management recent American guidelines
Reading File
Finding Sources
Searching PubMed
"migraine" AND "diagnosis" AND "treatment guidelines"
Searching the Web
American Headache Society migraine diagnosis management guidelines 2024 2025
Finding Sources
Reading Web Page
migraine diagnosis management guidelines recommendations
Searching PubMed
"migraine" AND "CGRP" AND "prevention"
Reading File
Reading File
Reading Article
Reading Article
Reading File
Searching the Web
ACP 2025 migraine prevention guideline recommendations CGRP first line
I now have sufficient data to compose a thorough, well-cited answer. Let me synthesize everything.
Migraine: Diagnosis and Management - Recent American Guidelines
Diagnosis
ICHD-3 Criteria (IHS, used in all US guidelines)
Migraine without aura requires at least 5 attacks fulfilling all of:
- Duration: 4-72 hours (untreated or treated unsuccessfully)
- At least 2 of the following headache features:
- Unilateral location
- Pulsating quality
- Moderate-to-severe intensity
- Aggravation by routine physical activity (walking, climbing stairs)
- During the attack, at least 1 of:
- Nausea and/or vomiting
- Photophobia AND phonophobia
Migraine with aura meets the above and includes neurological aura symptoms (visual, sensory, motor, or speech) that develop gradually, last 5-60 min, and are fully reversible. Visual aura is most common - classic fortification spectra (zigzag lines) with scotomata. Osmophobia, though not in the formal criteria, is highly specific when present.
- Bradley and Daroff's Neurology in Clinical Practice
Classification by frequency:
- Episodic migraine (EM): <15 headache days/month (affects ~12% of the population; 18% women, 6% men)
- Chronic migraine (CM): ≥15 headache days/month for >3 months, with ≥8 days meeting migraine criteria; prevalence ~2% of the general population
"Red Flag" Features Requiring Workup
The majority of migraineurs require NO diagnostic testing. Imaging (MRI brain) and further work-up are indicated for:
- "Thunderclap" onset or sudden worst headache of life
- Progressive or new headache >50 years
- Neurological symptoms outside typical aura
- Fever, meningismus, immunocompromised state
- Headache after head trauma
- Unexplained neurological exam findings
- Bradley and Daroff's Neurology in Clinical Practice
Acute (Abortive) Treatment
Outpatient
| Agent | Class | Notes |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, aspirin) | First-line mild-moderate | Aspirin-acetaminophen-caffeine combo has strong evidence |
| Triptans (sumatriptan, rizatriptan, etc.) | First-line moderate-severe | Serotonin 5-HT1B/1D agonists; contraindicated with uncontrolled HTN, CAD |
| Gepants (ubrogepant, rimegepant) | CGRP receptor antagonists | Oral; no vasoconstriction risk; can be used when triptans are contraindicated |
| Ditans (lasmiditan) | 5-HT1F agonist | No cardiovascular contraindications; CNS side effects |
| Antiemetics (metoclopramide, prochlorperazine) | Adjunct | Useful for nausea and as analgesic adjuncts |
The 2023 VA/DoD CPG (PMID 39467289) supports triptans as first-line for moderate-severe migraine attacks, and gepants (atogepant, rimegepant) as additional acute options alongside triptans.
Emergency Department - 2025 AHS Guideline Update
The 2025 AHS ED Guideline (Robblee et al., Headache 2026; PMID 41321235) is the most current American guideline for acute inpatient/ED management. It introduced the first two Level A recommendations in the field - meaning these treatments "MUST be offered":
Level A - MUST Offer:
- IV Prochlorperazine (upgraded from "should offer" in 2016)
- Greater Occipital Nerve Block (GONB) - first procedural therapy to achieve Level A
Level B - SHOULD Offer:
- IV metoclopramide
- IV ketorolac
- IV valproate sodium
- SC sumatriptan
- IV diphenhydramine (as adjunct to dopamine antagonists)
- SPG (sphenopalatine ganglion) blocks
Level C - May NOT Offer (avoid):
- IV opioids (morphine, hydromorphone) - actively discouraged for migraine pain
- IV acetaminophen/paracetamol
- IV diphenhydramine (as monotherapy)
- Octreotide IV
This guideline is the first ED-focused migraine guideline to formally evaluate a parenteral CGRP antagonist (eptinezumab IV), which showed superiority over placebo for acute migraine relief.
Preventive Treatment
Preventive therapy is recommended when:
- ≥4 migraine days/month with significant disability
- Acute medication overuse or failure
- Patient preference to reduce attack frequency
- Specific migraine subtypes (hemiplegic, basilar-type, migrainous infarction)
AHS 2024 Position Statement on CGRP Therapies
The American Headache Society (2024) issued a position statement that CGRP-targeting therapies should be a first-line option for migraine prevention - meaning clinicians do not need to require patients to "fail" older medications first before prescribing CGRP agents (Charles AC et al., Headache 2024).
ACP 2025 Clinical Guideline (Outpatient Episodic Migraine Prevention)
The American College of Physicians 2025 guideline (PMID 39899861) for episodic migraine (1-14 headache days/month) makes three conditional strength, low-certainty recommendations:
- Initiate monotherapy from one of these classes (considered comparable in efficacy, with cost as a differentiator):
- Beta-blockers (metoprolol, propranolol)
- Antiseizure medications (topiramate, valproate)
- Tricyclics (amitriptyline)
- ACE inhibitors (lisinopril) or ARBs (candesartan, telmisartan)
- SSRIs/SNRIs (fluoxetine, venlafaxine) - limited evidence
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)
- CGRP gepants (atogepant, rimegepant)
- Use alternative monotherapy if first agent is not tolerated or has inadequate response
- Patients/clinicians should weigh cost, adverse effects, and patient preferences
Important controversy: The AHS directly criticized the ACP guideline for overemphasizing cost, relying on older trials with outdated diagnostic criteria, and lacking headache specialists on the panel. The AHS maintains CGRP therapies have superior evidence quality from tens of thousands of trial participants vs. older preventives studied decades ago in small samples.
VA/DoD 2023 CPG Prevention Recommendations
The 2023 VA/DoD headache CPG (PMID 39467289) recommends for episodic migraine prevention:
- ARBs, lisinopril, magnesium, topiramate, valproate, memantine
- CGRP monoclonal antibodies
- Atogepant (gepant class, oral daily preventive)
- Aerobic exercise and physical therapy as adjuncts
- Gabapentin is NOT recommended for EM prevention
- OnabotulinumtoxinA recommended for chronic migraine only (not episodic)
Non-Pharmacologic Management
Supported across all guidelines:
- Identification and avoidance of triggers (alcohol, caffeine, hormonal changes, sleep disruption, stress, certain foods)
- Regular sleep schedule and aerobic exercise
- Biofeedback, cognitive behavioral therapy
- Physical therapy and yoga
- Textbook of Family Medicine 9e
Key Takeaways from Recent American Guidelines
| Guideline | Year | Main Focus | Key Change |
|---|---|---|---|
| AHS ED Guideline (Robblee et al.) | 2025 | Acute/ED | First Level A recs: IV prochlorperazine + GONB; opioids NOT recommended |
| AHS Position Statement (Charles et al.) | 2024 | Prevention | CGRP therapies = first-line; no step therapy required |
| ACP Clinical Guideline (Qaseem et al.) | 2025 | Outpatient prevention | CGRP comparable to older agents; cost should guide choice |
| VA/DoD CPG | 2023 | Comprehensive | 52 recommendations; gepants added; gabapentin not recommended for EM |
Sources:
- Bradley and Daroff's Neurology in Clinical Practice (definition, epidemiology, diagnostic criteria, genetics)
- Textbook of Family Medicine 9e (diagnostic criteria, acute and preventive treatment framework)
- Robblee J et al. 2025 AHS ED guideline. Headache 2026;66(1):53 [PMID 41321235]
- Qaseem A et al. ACP guideline. Ann Intern Med 2025;178(3) [PMID 39899861]
- Sico JJ et al. VA/DoD CPG. Ann Intern Med 2024 [PMID 39467289]
This is a shared conversation. Sign in to Orris to start your own chat.